Emergent Biosolutions Inc (EBS) CEO Sells $1,049,516.46 in Stock

Emergent Biosolutions Inc (NYSE:EBS) CEO Daniel Abdun-Nabi sold 21,906 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $47.91, for a total transaction of $1,049,516.46. Following the transaction, the chief executive officer now directly owns 226,040 shares of the company’s stock, valued at $10,829,576.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Daniel Abdun-Nabi also recently made the following trade(s):

  • On Wednesday, December 13th, Daniel Abdun-Nabi sold 20,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $45.99, for a total transaction of $919,800.00.
  • On Friday, November 3rd, Daniel Abdun-Nabi sold 31,508 shares of Emergent Biosolutions stock. The shares were sold at an average price of $42.77, for a total transaction of $1,347,597.16.

Shares of Emergent Biosolutions Inc (NYSE EBS) opened at $47.54 on Friday. Emergent Biosolutions Inc has a 52-week low of $27.94 and a 52-week high of $49.25. The company has a market cap of $1,944.76, a PE ratio of 24.86, a price-to-earnings-growth ratio of 0.98 and a beta of 1.25. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company had revenue of $149.43 million for the quarter, compared to the consensus estimate of $124.55 million. During the same period in the previous year, the firm earned $0.56 EPS. Emergent Biosolutions’s revenue was up 4.6% on a year-over-year basis. sell-side analysts anticipate that Emergent Biosolutions Inc will post 1.66 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its position in shares of Emergent Biosolutions by 0.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,224,198 shares of the biopharmaceutical company’s stock worth $89,968,000 after buying an additional 18,486 shares in the last quarter. Aberdeen Asset Management PLC UK raised its position in shares of Emergent Biosolutions by 7.3% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock worth $58,918,000 after buying an additional 118,894 shares in the last quarter. Royal Bank of Canada raised its position in shares of Emergent Biosolutions by 2.1% during the 2nd quarter. Royal Bank of Canada now owns 958,568 shares of the biopharmaceutical company’s stock worth $32,505,000 after buying an additional 19,833 shares in the last quarter. Northern Trust Corp raised its position in shares of Emergent Biosolutions by 47.2% during the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after buying an additional 290,863 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Emergent Biosolutions by 16.7% during the 2nd quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock worth $27,820,000 after buying an additional 117,700 shares in the last quarter. Institutional investors own 88.44% of the company’s stock.

A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Wells Fargo & Co reissued an “outperform” rating and set a $43.00 target price (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th.

COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/daniel-abdun-nabi-sells-21906-shares-of-emergent-biosolutions-inc-ebs-stock.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply